Clinical OMICs - Issue 4 - (Page 11)
Today, the majority of
initial cancer treatments
remain ineffective.
Cancer Genetics is changing the future of cancer
and dramatically improving treatment outcomes by focusing on a patient's
individual genetic information. We are positively impacting patient lives each day
through the development of a growing suite of innovative diagnostic solutions.
Our DNA-based oncology tests, which have been validated in collaboration with
leading cancer research centers, are ushering in a new era of cancer care.
Learn more at www.cancergenetics.com
terms of their value, and we are looking at all of those to potentially be an
overlay for our Foundation One tests."
Regardless of the source of genetic
material for gene sequencing diagnostics, improving the treatment of
cancer should only get more precise
in the coming years. As Miller noted, if
you charted a graph showing the
number of clinically relevant biomarkers discovered over the past ten years,
the curve would be very steep. "When
one sees the value of a predictive biomarker that is genomically faced and
the magnitude difference in outcomes that is possible when linking
that biomarker to a therapy, it changes
the fundamental equation around the
value of diagnostics and treatment,"
he concluded.
www.clinicalomics.com
May 29, 2014 Clinical OMICs
11
http://www.cancergenetics.com/
http://ir.cancergenetics.com/
https://www.facebook.com/CancerGenetics
https://twitter.com/Cancer_Genetics
https://www.linkedin.com/company/cancer-genetics-inc.
https://www.pinterest.com/cancergenetics/
http://www.cancergenetics.com/
http://www.liebertpub.com/omi
http://www.liebertpub.com/omi
http://www.clinicalomics.com
Table of Contents for the Digital Edition of Clinical OMICs - Issue 4
Contents
Clinical OMICs - Issue 4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue15
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue14
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue13
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue1
https://www.nxtbookmedia.com